TB-500 dosage and an uneven response
The most interesting dose in the rat stroke study is the one that failed to improve the outcome significantly. All amounts here describe experiments.
The tested rat doses
TB-500 dosage discussions often borrow amounts from full-length thymosin beta-4 research. In the Morris rat embolic-stroke study, male Wistar rats received the full protein intraperitoneally—into the abdominal cavity—at 2, 12 or 18 mg/kg. Administration started 24 hours after stroke and continued every three days for four more doses. These are the study's animal exposures, with no established human equivalent for the fragment.
Neurological function improved significantly in the 2 and 12 mg/kg groups from day 14 through day 56. At 18 mg/kg, there was no significant benefit. I regard the failure of the top tested amount to extend the lower-dose result as the most consequential finding in this dosing record.
The modeled optimum
The investigators proposed a modeled optimal dose of about 3.75 mg/kg. That figure came from a model; the listed administered groups received 2, 12 and 18 mg/kg. The dose-response paper supplies both kinds of information, and the distinction matters.
I want that high-dose result explained before treating the modeled optimum as a magic number. This experiment offers no validated dose for human TB-500 use. It also leaves open why the highest-dose group lacked a significant benefit. The data establish the reported pattern; they do not establish a mechanism for its disappearance.
Human intravenous exposure
The Phase 1 healthy-volunteer study used full-length synthetic thymosin beta-4 intravenously. The 40 volunteers were assigned to four cohorts of 10, with studied doses of 42, 140, 420 or 1260 mg: a single dose, followed by daily administration for 14 days. The preparation was well tolerated, with infrequent mild or moderate adverse events, no dose-limiting toxicities and no serious adverse events.
Those details describe a controlled study of a different molecule from the seven-residue fragment. It was a safety and pharmacokinetic study, and it establishes no injury-recovery benefit or usable human regimen for TB-500.
TB-500 half-life
No validated human pharmacokinetic half-life is established for the TB-500 heptapeptide. In the intravenous full-length-protein study, pharmacokinetics were dose-proportional and half-life increased with dose. The equine analysis of TB-500 and its metabolites concerns detection in horse plasma and urine.
Neither study lets me calculate an exposure interval for a person given the fragment. A detection method answers whether a substance can be found in a sample; a dosing interval requires evidence about exposure and effects in the relevant population.
Other research exposures
The mdx mouse study administered 150 µg of full-length thymosin beta-4 intraperitoneally twice weekly for six months. The rat wound study used topical or intraperitoneal thymosin beta-4 and also reported keratinocyte-migration activity at as little as 10 pg in cell assays. These examples show how widely the preparation, route and experimental question can differ.
Community “loading then maintenance” practices have no published validation in controlled human fragment trials. The review of unapproved peptide therapies emphasizes how little rigorous human safety evidence exists. The missing human pharmacokinetics and the uneven rat response leave those practices without a clinical foundation. This article supplies no dose recommendation or administration instructions.